Welcome to the SEER Inquiry System (SINQ). SINQ is a collection of questions that
cancer registrars have had while coding cancer cases. Click Search to look for
specific questions or to select questions for a Report.
Reportability--Corpus uteri: Is smooth muscle tumor with uncertain malignant potential (STUMP) reportable? See Discussion.
Reportability--Appendix: Is low grade appendiceal mucinous neoplasm (LAMN) reportable for 2018? It is staged as pTis(LAMN) AJCC 8th ed by pathologist.
First Course of Treatment/Surgery of Primary Site--Melanoma: How do you code UVB therapy treatment for melanoma?
Reportability--Skin: Is early/evolving lentigo maligna reportable?
Solid Tumor Rules (2018)--Breast: How many primaries are accessioned when a prophylactic mastectomy reveals a final diagnosis of invasive tubular carcinoma, but the College of American Pathologists (CAP) Protocol includes ductal carcinoma in situ (DCIS) sized separately and it is not clear if these are different tumors? See Discussion.
Date of diagnosis: The 2018 SEER Manual confirms the date of a suspicious cytology may be used to code the date of diagnosis when there is a subsequent definitive biopsy. Does this new instruction apply if the definitive biopsy or resection is performed 6 months following the suspicious cytology? See Discussion.
Primary site--Colon: What is the correct topography code for appendiceal orifice? See Discussion.
Reportability/Behavior: Is myxoinflammatory fibroblastic sarcoma (MIFS) reportable for 2018? This histology is on the 2018 ICD-O-3 histology update list with a behavior code of /1. See discussion.
Reportability/Histology: Is a focal high grade squamous intraepithelial lesion (HSIL/moderate to severe dysplasia/VIN II-III) in the vulva reportable for cases diagnosed in 2018? See discussion.
Solid Tumor Rules (2018)/Histology--Corpus uteri: What is the correct histology code for "Mesophrenic-like adenocarcinoma" of the corpus uteri?" See Discussion.